Microbiota-targeted strategies in IBD: therapeutic promise of 2′-fucosyllactose and beyond
Issued Date
2025-01-01
Resource Type
ISSN
1756283X
eISSN
17562848
Scopus ID
2-s2.0-105020408203
Journal Title
Therapeutic Advances in Gastroenterology
Volume
18
Rights Holder(s)
SCOPUS
Bibliographic Citation
Therapeutic Advances in Gastroenterology Vol.18 (2025)
Suggested Citation
Fanous N., Talley N.J., Chaemsupaphan T., Lee E., Rayamajhee B., Baradaran Ghavami S., Kazemifard N., Asadzadeh Aghdaei H., Chuang E., Leong R.W. Microbiota-targeted strategies in IBD: therapeutic promise of 2′-fucosyllactose and beyond. Therapeutic Advances in Gastroenterology Vol.18 (2025). doi:10.1177/17562848251386319 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112951
Title
Microbiota-targeted strategies in IBD: therapeutic promise of 2′-fucosyllactose and beyond
Author's Affiliation
UNSW Sydney
Shahid Beheshti University of Medical Sciences
Siriraj Hospital
St. Vincent's Hospital Sydney
Concord Repatriation General Hospital
School of Medicine and Public Health
Orange Health Service
NHMRC Centre of Research Excellence in Digestive Health
Macquarie Medical School
School of Optometry and Vision Sciences
Intrinsic Medicine
Shahid Beheshti University of Medical Sciences
Siriraj Hospital
St. Vincent's Hospital Sydney
Concord Repatriation General Hospital
School of Medicine and Public Health
Orange Health Service
NHMRC Centre of Research Excellence in Digestive Health
Macquarie Medical School
School of Optometry and Vision Sciences
Intrinsic Medicine
Corresponding Author(s)
Other Contributor(s)
Abstract
Inflammatory bowel diseases (IBD) are chronic and recurrent conditions of the gastrointestinal tract. IBD is often challenging to manage due to the complex etiology and involvement of multiple dysregulated immune pathways. Current treatments, including biologics and immunosuppressants, are associated with significant risks and side effects, highlighting the need for safer alternatives. Human milk oligosaccharides (HMOs), a group of bioactive carbohydrates found in human breast milk, play a crucial role in shaping the infant gut microbiome, modulating microbial metabolism and immune responses, and reducing inflammation. Notably, HMOs have no nutritional value for the infant and travel undigested through the upper gastrointestinal tract, serving as selective substrates for beneficial gut bacteria and supporting intestinal epithelial health. Among these, 2′-fucosyllactose (2′-FL) is the most abundant and well-studied HMO, functioning as a trisaccharide prebiotic. Emerging evidence suggests that the benefits of HMOs extend beyond infancy, with potential therapeutic applications in modulating immune responses, promoting epithelial health, and reducing inflammation in IBD. This review summarizes current research on the role of 2′-FL in inflammation and colitis, exploring its potential role in treating IBD.